Concepedia

Author

Jenny Han

AstraZeneca (United States)

Also Known As

Jenny Han, Michael Trautmann

35

Publications

4.4K

Citations

18

H-Index

6

Concepts

All Affiliations

AstraZeneca (United States)Patara Pharma (United States)Eli Lilly (United States)Amplyx Pharmaceuticals (United States)Bristol-Myers Squibb (United States)
JH

About

Jenny Han is an author at AstraZeneca (United States) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

246

2

Pharmacology

2

2

246

3

Diabetes

1

1

152

4

Clinical Trials

1

1

152

5

Pharmacokinetics

1

1

94

Jenny Han

×

20

Publications

4K

Citations

16

H-Index

YearCitations

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, Robert E. Ratner, Jenny Han,

Diabetes Care

2005

1.5K

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

John B. Buse, Robert R. Henry, Jenny Han,

Diabetes Care

2004

1.3K

Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia

Kristine B. Degn, Birgitte Brock, Claus Bogh Juhl,

Diabetes

2004

253

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Bruno Guerci,

The Lancet Diabetes & Endocrinology

2014

152

A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)

Federico Calara, Kristin Taylor, Jenny Han,

Clinical Therapeutics

2005

94

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

Amalia Gastaldelli, Enrico Repetto, Cristian Guja,

Diabetes Obesity and Metabolism

2019

75

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: <scp>I</scp> ncidence and consequences

Michael Horowitz, Vanita R. Aroda, Jenny Han,

Diabetes Obesity and Metabolism

2017

71

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

Kristin Taylor, Kate Gurney, Jenny Han,

BMC Endocrine Disorders

2011

66

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

Michael Grimm, Jenny Han, Carole Weaver,

Postgraduate Medicine

2013

63

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

Kate Gurney, Leigh MacConell, Carl J. Brown,

Diabetes Metabolic Syndrome and Obesity

2012

61

Page 1